R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

Featured Content

R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

Newsletters and Deep Dive
digital magazine

Latest News

Views & Analysis

R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

Deep Dive

White Papers & Webinar

on demand
Digital
How AI is supercharging clinical trials
Sponsored

How AI is supercharging clinical trials

Artificial intelligence (AI) and machine learning are here to stay, so it’s crucial to understand how they can be used to the best effect in the evolving world of clinical trials.<

Podcasts & Video

R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica

R&D
pharmaphorum podcast Episode 113

Pharmaceutical research in space

When US President Joe Biden talks about his Cancer Moonshot, he's not literally talking about the moon - he's referencing the legendary innovation push that got Americans to the moon in 196

Partner Content